Depression, antidepressant use, and breast cancer incidence: results from the <scp>E3N</scp> prospective cohort
These findings from a prospective cohort suggest that depression and antidepressant drugs exert opposing effects on breast cancer incidence. While these results require replication in future studies, they could help promote adherence to antidepressant drugs in women with depression.
Authors
- Océane Mohamed
- Romain Colle (ORCID: https://orcid.org/0000-0002-2549-4495)
- A. Fournier (ORCID: https://orcid.org/0000-0001-8380-3439)
- Éric Deflesselle
- Marie‐Christine Boutron‐Ruault (ORCID: https://orcid.org/0000-0002-5956-5693)
- Bruno Falissard
- Gianluca Severi (ORCID: https://orcid.org/0000-0001-7157-419X)
- Emmanuelle Corruble
Institutions
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre de recherche en Epidémiologie et Santé des Populations (FR)
- Bicêtre Hospital (FR)
- University of Florence (IT)
Publication Details
- Journal
- Psychiatry and Clinical Neurosciences
- Published
- 2025-06-17
- DOI
- https://doi.org/10.1111/pcn.13852
- Primary Topic
- Cancer-related cognitive impairment studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Les Laboratories Pierre Fabre
- Agence Nationale de la Recherche
- Daiichi-Sankyo
- Ligue Contre le Cancer
- Astellas Pharma
- Institut Gustave-Roussy
- Mutuelle Générale de l'Education Nationale
- Servier
- H. Lundbeck A/S
- Allergan